Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122


Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion.

Embry A, Meng X, Cantwell A, Dube PH, Xiang Y.

Vaccine. 2011 Jul 26;29(33):5331-9. doi: 10.1016/j.vaccine.2011.05.088. Epub 2011 Jun 12.


A bivalent typhoid live vector vaccine expressing both chromosome- and plasmid-encoded Yersinia pestis antigens fully protects against murine lethal pulmonary plague infection.

Galen JE, Wang JY, Carrasco JA, Lloyd SA, Mellado-Sanchez G, Diaz-McNair J, Franco O, Buskirk AD, Nataro JP, Pasetti MF.

Infect Immun. 2015 Jan;83(1):161-72. doi: 10.1128/IAI.02443-14. Epub 2014 Oct 20.


LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Sun W, Sanapala S, Henderson JC, Sam S, Olinzock J, Trent MS, Curtiss R 3rd.

Infect Immun. 2014 Oct;82(10):4390-404. doi: 10.1128/IAI.02173-14. Epub 2014 Aug 11.


Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge.

Branger CG, Sun W, Torres-Escobar A, Perry R, Roland KL, Fetherston J, Curtiss R 3rd.

Vaccine. 2010 Dec 16;29(2):274-82. doi: 10.1016/j.vaccine.2010.10.033. Epub 2010 Oct 24.


Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.

Sanapala S, Rahav H, Patel H, Sun W, Curtiss R.

Vaccine. 2016 May 5;34(21):2410-6. doi: 10.1016/j.vaccine.2016.03.094. Epub 2016 Apr 6.


Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.

Miller NC, Quenee LE, Elli D, Ciletti NA, Schneewind O.

Infect Immun. 2012 Apr;80(4):1572-82. doi: 10.1128/IAI.05637-11. Epub 2012 Jan 17.


Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.

Wang S, Goguen JD, Li F, Lu S.

Vaccine. 2011 Sep 9;29(39):6802-9. doi: 10.1016/j.vaccine.2010.12.062. Epub 2011 Jan 1.


Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.

Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK.

Vaccine. 2008 Nov 25;26(50):6329-37. doi: 10.1016/j.vaccine.2008.09.031. Epub 2008 Oct 1.


A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.

Wang S, Heilman D, Liu F, Giehl T, Joshi S, Huang X, Chou TH, Goguen J, Lu S.

Vaccine. 2004 Sep 3;22(25-26):3348-57.


Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.

Brewoo JN, Powell TD, Stinchcomb DT, Osorio JE.

Vaccine. 2010 Aug 16;28(36):5891-9. doi: 10.1016/j.vaccine.2010.06.054. Epub 2010 Jul 12.


Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.

Bhattacharya D, Mecsas J, Hu LT.

Vaccine. 2010 Nov 10;28(48):7683-9. doi: 10.1016/j.vaccine.2010.09.039. Epub 2010 Sep 25.


Different strategies for preparation of non-tagged rV270 protein and its efficacy against Yersinia pestis challenge.

Wang W, Qi ZZ, Zhang QW, Wu BC, Zhu ZW, Yang YH, Cui BZ, Dai RX, Qiu YF, Wang ZY, Guo ZB, Shi TX, Wang H, Yang RF, Wang XY.

Biomed Environ Sci. 2010 Oct;23(5):333-40. doi: 10.1016/S0895-3988(10)60073-6.


Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.

Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW.

Microb Pathog. 1997 Sep;23(3):167-79.


Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270.

Qi Z, Zhou L, Zhang Q, Ren L, Dai R, Wu B, Wang T, Zhu Z, Yang Y, Cui B, Wang Z, Wang H, Qiu Y, Guo Z, Yang R, Wang X.

Vaccine. 2010 Feb 10;28(6):1655-60. doi: 10.1016/j.vaccine.2009.02.078. Epub 2009 Mar 9.


HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model.

Batra L, Verma SK, Nagar DP, Saxena N, Pathak P, Pant SC, Tuteja U.

PLoS Negl Trop Dis. 2014 Dec 4;8(12):e3322. doi: 10.1371/journal.pntd.0003322. eCollection 2014 Dec.


Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.

DeBord KL, Anderson DM, Marketon MM, Overheim KA, DePaolo RW, Ciletti NA, Jabri B, Schneewind O.

Infect Immun. 2006 Aug;74(8):4910-4.


A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague.

Chichester JA, Musiychuk K, Farrance CE, Mett V, Lyons J, Mett V, Yusibov V.

Vaccine. 2009 May 26;27(25-26):3471-4. doi: 10.1016/j.vaccine.2009.01.050. Epub 2009 Feb 5.


Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.

Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, Shafferman A, Flashner Y, Mamroud E.

Vaccine. 2008 Mar 20;26(13):1616-25. doi: 10.1016/j.vaccine.2008.01.033. Epub 2008 Feb 6.


A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.

Sha J, Kirtley ML, Klages C, Erova TE, Telepnev M, Ponnusamy D, Fitts EC, Baze WB, Sivasubramani SK, Lawrence WS, Patrikeev I, Peel JE, Andersson JA, Kozlova EV, Tiner BL, Peterson JW, McWilliams D, Patel S, Rothe E, Motin VL, Chopra AK.

Clin Vaccine Immunol. 2016 Jul 5;23(7):586-600. doi: 10.1128/CVI.00150-16. Print 2016 Jul.

Supplemental Content

Support Center